Jonathan Zalevsky
Chief Tech/Sci/R&D Officer chez NEKTAR THERAPEUTICS
Fortune : 247 533 $ au 31/03/2024
Profil
Jonathan Zalevsky is currently a Director at ReAlta Life Sciences, Inc. He is also an Independent Director at Invea Therapeutics, Inc. since 2021.
Prior to his current positions, he served as the Chief Research & Development Officer at Nektar Therapeutics starting in 2015.
Previously, he worked at Takeda Pharmaceuticals U.S.A., Inc. as the Global VP & Head-Inflammation Drug Discovery Unit.
Dr. Zalevsky holds a doctorate degree from The University of California, San Francisco and an undergraduate degree from the University of Colorado Boulder.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NEKTAR THERAPEUTICS
0,14% | 20/02/2024 | 265 025 ( 0,14% ) | 247 533 $ | 31/03/2024 |
Postes actifs de Jonathan Zalevsky
| Sociétés | Poste | Début |
|---|---|---|
| NEKTAR THERAPEUTICS | Chief Tech/Sci/R&D Officer | 01/07/2015 |
ReAlta Life Sciences, Inc.
 ReAlta Life Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services ReAlta Life Sciences, Inc. is a biotech company dedicated to harnessing the power of immune system through PIC1 technology. The company was founded in 2018 and is headquartered in Norfolk, VA. | Director/Board Member | - |
Invea Therapeutics, Inc.
 Invea Therapeutics, Inc. BiotechnologyHealth Technology Invea Therapeutics, Inc. operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases. Its products include INVA8001 and INVA8003. The company was founded on October 20, 2021. The company is headquartered in Guilford, CT. | Director/Board Member | 01/11/2021 |
Anciens postes connus de Jonathan Zalevsky
| Sociétés | Poste | Fin |
|---|---|---|
Takeda Pharmaceuticals U.S.A., Inc.
 Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Corporate Officer/Principal | - |
Formation de Jonathan Zalevsky
| The University of California, San Francisco | Doctorate Degree |
| University of Colorado Boulder | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NEKTAR THERAPEUTICS | Health Technology |
| Entreprise privées | 3 |
|---|---|
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Health Technology |
ReAlta Life Sciences, Inc.
ReAlta Life Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services ReAlta Life Sciences, Inc. is a biotech company dedicated to harnessing the power of immune system through PIC1 technology. The company was founded in 2018 and is headquartered in Norfolk, VA. | Commercial Services |
Invea Therapeutics, Inc.
Invea Therapeutics, Inc. BiotechnologyHealth Technology Invea Therapeutics, Inc. operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases. Its products include INVA8001 and INVA8003. The company was founded on October 20, 2021. The company is headquartered in Guilford, CT. | Health Technology |
